Calais Jérémie, Thureau Sébastien, Dubray Bernard, Modzelewski Romain, Thiberville Luc, Gardin Isabelle, Vera Pierre
Nuclear Medicine Department, Henri Becquerel Cancer Center and Rouen University Hospital, Rouen, France QuantIF-LITIS (EA [Equipe d'Accueil] 4108-FR CNRS [Fédération de Recherche-Centre National pour la Recherche Scientifique] 3638), Faculty of Medicine, University of Rouen, Rouen, France.
Nuclear Medicine Department, Henri Becquerel Cancer Center and Rouen University Hospital, Rouen, France QuantIF-LITIS (EA [Equipe d'Accueil] 4108-FR CNRS [Fédération de Recherche-Centre National pour la Recherche Scientifique] 3638), Faculty of Medicine, University of Rouen, Rouen, France Department of Radiotherapy and Medical Physics, Henri Becquerel Cancer Centre and Rouen University Hospital, Rouen, France; and.
J Nucl Med. 2015 Feb;56(2):196-203. doi: 10.2967/jnumed.114.144253. Epub 2015 Jan 8.
The high rates of failure in the radiotherapy target volume suggest that patients with stage II or III non-small cell lung cancer (NSCLC) should receive an increased total dose of radiotherapy. Areas of high (18)F-FDG uptake on preradiotherapy (18)F-FDG PET/CT have been reported to identify intratumor subvolumes at high risk of relapse after radiotherapy. We wanted to confirm these observations on a cohort of patients included in 3 sequential prospective studies. Our aim was to assess an appropriate threshold (percentage of maximum standardized uptake value [SUVmax]) to delineate subvolumes on staging (18)F-FDG PET/CT scans assuming that a smaller target volume would facilitate isotoxic radiotherapy dose escalation.
Thirty-nine patients with inoperable stage II or III NSCLC, treated with chemoradiation or with radiotherapy alone, were extracted from 3 prospective studies (ClinicalTrials.gov identifiers NCT01261585, NCT01261598, and RECF0645). All patients underwent (18)F-FDG PET/CT at initial staging, before radiotherapy, during radiotherapy, and during systematic follow-up in a single institution. All (18)F-FDG PET/CT acquisitions were coregistered on the initial scan. Various subvolumes in the initial acquisition (30%, 40%, 50%, 60%, 70%, 80%, and 90% SUVmax thresholds) and in the 3 subsequent acquisitions (40% and 90% SUVmax thresholds) were pasted on the initial scan and compared.
Seventeen patients had a local relapse. The SUVmax measured during radiotherapy was significantly higher in locally relapsed tumors than in locally controlled tumors (mean, 6.8 vs. 4.6; P = 0.02). The subvolumes delineated on initial PET/CT scans with 70%-90% SUVmax thresholds were in good agreement with the recurrent volume at a 40% SUVmax threshold (common volume/baseline volume, 0.60-0.80). The subvolumes delineated on initial PET/CT scans with 30%-60% SUVmax thresholds were in good to excellent agreement with the core volume of the relapse (90% SUVmax threshold) (common volume/recurrent volume and overlap fraction indices, 0.60-0.93). The agreement was moderate (>0.51) when a 70% SUVmax threshold was used to delineate on initial PET/CT scans.
High (18)F-FDG uptake areas on pretreatment PET/CT scans identify tumor subvolumes at greater risk of relapse in patients with NSCLC treated by concomitant chemoradiation. We propose a 70% SUVmax threshold to delineate areas of high (18)F-FDG uptake on initial PET/CT scans as the target volumes for potential radiotherapy dose escalation.
放射治疗靶区的高失败率表明,II期或III期非小细胞肺癌(NSCLC)患者应接受更高的放射治疗总剂量。据报道,放疗前(18)F-FDG PET/CT上高(18)F-FDG摄取区域可识别放疗后复发风险高的肿瘤内亚体积。我们想在3项连续的前瞻性研究纳入的一组患者中证实这些观察结果。我们的目的是评估一个合适的阈值(最大标准化摄取值[SUVmax]的百分比),以便在分期(18)F-FDG PET/CT扫描上勾勒亚体积,假设较小的靶区体积将有助于等毒性放疗剂量增加。
从3项前瞻性研究(ClinicalTrials.gov标识符NCT01261585、NCT01261598和RECF0645)中提取39例无法手术的II期或III期NSCLC患者,这些患者接受了放化疗或单纯放疗。所有患者在初始分期、放疗前、放疗期间以及在单一机构进行系统随访期间均接受了(18)F-FDG PET/CT检查。所有(18)F-FDG PET/CT采集均与初始扫描进行配准。将初始采集(30%、40%、50%、60%、70%、80%和90% SUVmax阈值)以及随后3次采集(40%和90% SUVmax阈值)中的各种亚体积粘贴到初始扫描上并进行比较。
17例患者出现局部复发。局部复发肿瘤放疗期间测得的SUVmax显著高于局部控制肿瘤(平均值分别为6.8和4.6;P = 0.02)。初始PET/CT扫描上以70%-90% SUVmax阈值勾勒的亚体积与40% SUVmax阈值时的复发体积高度一致(共同体积/基线体积,0.60-0.80)。初始PET/CT扫描上以30%-60% SUVmax阈值勾勒的亚体积与复发核心体积(90% SUVmax阈值)高度一致(共同体积/复发体积和重叠分数指数,0.60-0.93)。当使用70% SUVmax阈值在初始PET/CT扫描上进行勾勒时,一致性为中等(>0.51)。
治疗前PET/CT扫描上高(18)F-FDG摄取区域可识别接受同步放化疗的NSCLC患者中复发风险更高的肿瘤亚体积。我们建议使用70% SUVmax阈值在初始PET/CT扫描上勾勒高(18)F-FDG摄取区域,作为潜在放疗剂量增加的靶区体积。